Clinical Applications of FDG PET and PET/CT in  Head and Neck Cancer by Al-Ibraheem, Akram et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2009, Article ID 208725, 13 pages
doi:10.1155/2009/208725
Review Article
ClinicalApplications of FDG PET and PET/CT in
Head and Neck Cancer
Akram Al-Ibraheem, Andreas Buck, Bernd Joachim Krause, Klemens Scheidhauer,
andMarkus Schwaiger
Department of Nuclear Medicine, Technische Universit¨ at M¨ unchen, Ismaninger Strasse 22, 81675 Munich, Germany
Correspondence should be addressed to Akram Al-Ibraheem, akramalibrahim@gmail.com
Received 28 February 2009; Accepted 17 June 2009
Recommended by Paul Harari
18F-FDG PET plays an increasing role in diagnosis and management planning of head and neck cancer. Hybrid PET/CT has
promoted the ﬁeld of molecular imaging in head and neck cancer. This modality is particular relevant in the head and neck
region,giventhecomplexanatomyandvariablephysiologicFDGuptakepatterns.Thevastmajorityof18F-FDGPETandPET/CT
applicationsinheadandneckcancerrelatedtoheadandnecksquamouscellcarcinoma.Clinicalapplicationsof18F-FDGPETand
PET/CT in head and neck cancer include diagnosis of distant metastases, identiﬁcation of synchronous 2nd primaries, detection
of carcinoma of unknown primary and detection of residual or recurrent disease. Emerging applications are precise delineation
of the tumor volume for radiation treatment planning, monitoring treatment, and providing prognostic information. The clinical
roleof18F-FDGPET/CTinN0diseaseislimitedwhichisinlinewithﬁndingsofotherimagingmodalities.MRIisusuallyusedfor
TstagingwithanintensediscussionconcerningthepreferableimagingmodalityforregionallymphnodestagingasPET/CT,MRI,
and multi-slice spiral CT are all improving rapidly. Is this review, we summarize recent literature on 18F-FDG PET and PET/CT
imaging of head and neck cancer.
Copyright © 2009 Akram Al-Ibraheem et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
In 2008, head and neck cancers accounted for approximately
4% to 5% of all the malignant disease in the United States
[1]. Head and neck squamous cell carcinoma (HNSCC)
comprises the vast majority of head and neck cancer (HNC).
Oncologic imaging plays an important role in head and neck
cancers as imaging ﬁndings can aid signiﬁcantly detection,
staging, restaging, and therapy response assessment of
these tumors. Accurate staging at the time of diagnosis is
critical for selection of the appropriate treatment strategy.
Unfortunately,atthe time of initial diagnosis more than50%
of patients already present with regional nodal metastases or
even distant metastases.
Diagnosis of a head and neck cancer is usually achieved
by a combination of patient history, physical examination,
and either nasopharyngoscopy and/or laryngoscopy with
directed biopsies. Panendoscopy may be necessary to reveal
the extent of a tumor. Morphologic imaging with computed
tomography (CT) and/or magnetic resonance imaging
(MRI) with intravenous contrast are often performed either
prior to panendoscopy to noninvasively assess the aerodi-
gestive tract or afterwards to provide information about
primary tumor size, inﬁltration, involvement of surrounding
structures, and regional nodal involvement. There is growing
evidence, however, that these modalities have limitations
in their diagnostic accuracy. CT and MR imaging rely on
criteria of contrast-enhancement patterns and nodal size for
detection of lymph node metastases which are not speciﬁc
and may escape detection of metastases within normal size
lymph nodes. There is also growing evidence that 18F-FDG
PET imaging is a very sensitive and valuable imaging tool
in evaluation head and neck cancer. The main drawback of
18F-FDG PET alone is the limitation with respect to lesion
localization. However, the advent of PET/CT now overcomes
this limitation and permits the evaluation of both metabolic
and anatomic characteristics of disease, which has proven
to be a major advance for staging, detection carcinoma of2 Journal of Oncology
Table 1: Studies comparing accuracy of FDG PET and PET/CT with CT and MRI for detection of lymph nodes metastases.
Author year Number of patients Tumor Subtypes Results Notes
Beak et al. [2], 2009 15 Periorbital PET/CT accuracy (98%) >
CT 84%
-C T :1 6s l i c e .
- PET modiﬁed Tx in 39%.
Roh et al. [3], 2007 167 HNSCC




better for detection of
primary tumor
Gordin et al. [4], 2007 35 Nasopharyngeal PET/CT accuracy 91% >
PET 80% > CT 60%
-R e t r o s p e c t i v e
- PET/CT modiﬁed TX in
57%
Kim et al. [5], 2007 32 Oropharyngeal PET sensitivity 21% higher
than CT/MR (P<. 05)
- PET/CT signiﬁcantly
better for detection of
primary tumor
Dammann et al. [6], 2005 79 Oral cavity and oropharynx PET accuracy 96% > MRI
94% > CT 92%
- Nonhyprid PET/CT used
Ng et al. [7], 2005 124 Oral cavity SCC PET accuracy 98.4% >
CT/MR 87.1% -P r o s p e c t i v e
unknown primary, treatment monitoring, and evaluation of
residual or recurrent disease.
2. Staging
Accurate staging at the time of diagnosis is the most
important factor for treatment planning and determination
of prognosis [8]. One attractive feature of 18F-FDG PET as
a modality for initial TNM staging is that it covers most
of the body within a single study. PET therefore provides
information on the primary tumor, nodal metastases, dis-
tant metastases, and potential 2nd primary carcinomas. A
literature survey on the use of 18F-FDG PET in head and
neck cancer (HNC) compared to CT indicates that PET has
a higher sensitivity (87% versus 62%) and speciﬁcity (89%
versus 73%) for staging cancer [9]. Addition of PET/CT to
initial staging of patients with HNC has also been shown to
haveameasurableimpactonthetreatmentselection[10,11].
2.1. Primary Tumor. Numerous reports on initial staging
have shown that 18F-FDG PET is at least as sensitive as MRI
or CT in detecting the primary tumor [3, 7, 10–17]. This is
related to the fact that smaller or submucosal malignancies
may be diﬃcult to distinguish from adjacent tissues on
anatomical imaging. A better sensitivity of 18F-FDG PET
for detecting primary tumor comparing to CT/MRI imaging
has been shown in oral cavity cancer [18, 19]. However,
the current practice is not in favor of utilizing 18F-FDG
PET for local staging of all newly diagnosed head and neck
squamous cell carcinoma (HNSCC). This is due to the
higher anatomic resolution of MRI and contrast enhanced
multislice CT compared to 18F-FDG PET. Nevertheless, in
a recent study by Baek et al. including 40 patients with
oral cavity cancer and dental artifacts on CT or MRI,
it was demonstrated that 18F-FDG PET/CT can provide
more useful clinical information and higher sensitivity,
particularly in deep tumors, compared to CT and MR. The
diagnostic performance for the detection of the primary
tumors in the oral cavity was 96.3% for PET/CT, 77.8% for
CT, and 85.2% for MRI [20].
2.2. Nodal Metastases. Nodal staging has a signiﬁcant impact
on outcome in terms of disease free survival and overall
survival after therapy [21]. Metastatic lymph node disease
is found in approximately 50% of the patients at the time
of primary diagnosis [6, 22]. Several reports have veriﬁed
that 18F-FDG PET has a higher sensitivity and speciﬁcity
t h a nC To rM Ri m a g i n gf o rd e t e c t i o no fl y m p hn o d e
metastases in head and neck cancer [23, 24]. In a review by
Sch¨ oder and Yeung, an average sensitivity of 87%–90% and a
speciﬁcity of 80%–93% were reported for 18F-FDG PET/CT;
a sensitivity of 61%–97% and speciﬁcity of 21%–100% were
reportedformorphologicimagingmodalitiesincludingMRI
and CT [25]. Several recent studies comparing 18F-FDG
PET, 18F-FDG PET/CT, and CT/MR are summarized in
Table 1. Results showed that integrated 18F-FDG PET/CT
may play an important role in identifying lymph node
metastases in head and neck squamous cell carcinoma
(HNSCC). However, MRI is usually used for local staging as
it provides almost comparable accuracy to 18F-FDG PET in
locoregional metastases in addition to best primary tumor
delineation [26].
Occult lymph nodes (clinical N0 disease) still represent
a dilemma for both imaging modalities and surgeons.
Although earlier reports have favored PET over other
anatomic imaging modalities as PET has been shown to have
a sensitivity of 78% and an accuracy of 92% (compared
with a sensitivity of 57% and an accuracy of 76% for CT)
for the detection of nodal metastases in clinical N0 disease
[27]. Two recent reports by Nahmias et al. and Schoder et
al. comprising 47 and 37 patients, respectively, demonstrated
that 18F-FDG PET/CT is not accurate enough for detectionJournal of Oncology 3
Figure 1: A 61-year-old man with nasopharyngeal SCC and bilateral cervical lymph node metastases underwent PET/CT for staging. Axial
PET, CT, PET/CT, and maximum intensity projection (MIP) images are shown. PET/CT revealed focal FDG uptake in the right liver lobe
indicating liver metastasis (black, white arrows). PET/CT also revealed multiple focal FDG uptakes in the lumbar spine, sternum, and ribs
indicating multiple bone metastases (red arrows). PET/CT was valuable for detection distant metastases.
of occult nodal disease in previously untreated patient and
would not help the surgeon in the management strategy
of the patient, particularly if the study is negative. They
reported sensitivity and a speciﬁcity ranging from 67% to
79% and 82% to 95%, respectively. False negative ﬁndings
were likely related to either the presence of microscopic
metastases not detected by PET/CT, or by the proximity of
nodal metastases to the primary tumor which might have
obscured their detection [28, 29]. Schroeder et al. veriﬁed
these results and suggested that elective neck dissection in
patients with clinical N0 head and neck cancer squamous
cell carcinoma (HNSCC) should not be based upon cross-
sectional imaging (CT, MR, PET/CT) at the resolutions
currently available [30]. However, Kovacs et al. examined the
potential role of 18F-FDG PET and sentinel node biopsy in
62 patients for the purpose of neck dissection. Their results
suggest that patients showing positive lymph node on PET
scan undergo a neck dissection due to the high speciﬁcity,
whereas a sentinel node biopsy should be performed in
patients with a negative PET scan. This strategy avoided
12 patients futile neck dissections with false-positive CT
ﬁndings and a negative sentinel node biopsy [31].
2.3. Distant Staging. The role of 18F-FDG PET for staging
of distant metastases in HNC is acknowledged as one of
the most powerful indication in HNC (Figure 1). There is
a general agreement that 18F-FDG PET is indicated for
initial staging of HNC when there is suspicious of distant
metastases and synchronous 2nd tumor. The incidence
distant metastases increases with locally advanced disease
(T3-T4), N2, or N3 disease, extracapsular extension of
lymph node involvement, and perineural invasion [32, 33].
A synchronous 2nd tumor, particularly in aerodigestive
tract, is often associated with a history of heavy nicotine
or alcohol consumption and patients with hypopharyngeal
tumors. Recent studies on the use of 18F-FDG PET for the
detection of distant metastases and synchronous 2nd tumor
in HNC are summarized in Table 2. These studies showed
that PET detected distant metastases or 2nd primaries in
up to 15.6% of the patients. The true positive ﬁndings were
82%. Moreover, PET showed a better accuracy once it was
compared to conventional imaging as demonstrated by Ng et
al., Chua et al., and Liu et al. [34–36].
3. Carcinomaof Unknown Primary
Cervical lymph node metastases from an unknown primary
tumor account for approximately 1-2% of newly diagnosed
head and neck cancers [40]. In 5% to 80%, depending on the
patient selection, the primary tumor could not be identiﬁed
by physical examination, panendoscopy, and conventional
imaging, including CT and/or MRI [41, 42]. Treatment of
these patients often includes extensive ﬁelds of irradiation to
include the entire pharyngeal mucosa, larynx, and bilateral
neck. The wide-ﬁeld irradiation reduces the risk of tumor
recurrence. However, it also causes signiﬁcant morbidity,
particularly in terms of xerostomia [43]. Therefore, the
accurate identiﬁcation of occult primary sites is important
because the therapy can then be focused to the known
site of origin, decreasing treatment-related morbidity, and
improving therapeutic eﬃcacy [44].
The utility of 18F-FDG PET to identify carcinomas of
unknown primary has been examined. A comprehensive
review by Rusthoven summarized the impact of 18F-FDG4 Journal of Oncology
Table 2: Studies evaluating the performance of FDG PET for the detection of distant metastases and synchronous 2nd tumor in HNC.
Author year Number of patients Positive PET True positive (distant
mets + 2nd primary)
False positive Notes
Ng et al. [34], 2009 111 16 13/16 3/16 CT/MR detect 4/16
Chua et al. [35],
2009
68 6 5/6 1/6 CT + BS detect 4/6
Liu et al. [36], 2007 300 61 50/61 11/61
Yen et al. [37],
2005
118 32 24/32 8/32
Goerres et al. [12],
2003
34 8 7/8 1/8 PET modiﬁed Treatment in 15%
Sigg et al. [38],
2003
58 8 7/8 1/8 PET modiﬁed Treatment in 5%
Schwartz et al.
[39], 2003
33 7 7/7 0/7
Total 722 138 113/138 25/138
PET for the situation of carcinoma of unknown primary.
A total of 16 studies comprising 302 patients, published
between1994and2003,wereincluded.Inallofthesestudies,
patients underwent physical examination and CT or MRI,
with the majority undergoing panendoscopy as well. The
gold standard for primary tumor veriﬁcation was tissue
biopsy. Of the 302 patients, 18F-FDG PET detected 24.5%
of tumors that were not apparent after conventional workup.
18F-FDG PET imaging also led to the detection of previously
unknown metastases in 27.1% of the patients (regional,
15.9%; distant, 11.2%). The overall of sensitivity of PET for
the primary tumor detection was 88%, with a speciﬁcity of
75%, and an accuracy of 79%. When detection eﬃcacy was
evaluated with respect to localization, a lower sensitivity for
cancers in base of tongue, and a lower speciﬁcity for cancers
in the tonsil were noted [45]. In this review, we performed
a meta-analysis including studies published between 2000
and 2009 that speciﬁcally addressed the performance of 18F-
FDG PET or PET/CT in detecting carcinoma of unknown
primary in patients presented with cervical lymph node
metastases and negative or inconclusive standard workup.
For this group, 18F-FDG PET and PET/CT detected the
primary tumor in 51 of 180 patients (28%) (Table 3).
Two recent reports in the era of advanced morphologic
imaging technology also veriﬁed the vital utility of 18F-FDG
PET and PET/CT in cancer of unknown origin. Johansen
et al. showed in a prospective study comprising 67 patients
with cancer of unknown primary that a therapeutic change
of treatment was made in 25% as a consequence of 18F-FDG
PET ﬁndings [54]. Roh et al. compared the performance of
combined 18F-FDG PET/CT and CT alone in 44 patients
with cervical metastases from unknown primary tumors.
They reported that 18F-FDG PET/CT was signiﬁcantly more
sensitive than CT (94.0% versus 71.6%, P<. 001), but
the two methods had similar speciﬁcities (94.8% versus
96.5%, resp.). 18F-FDG PET/CT correctly detected distant
metastases in 6 out of 6 patients [55]. Based on these
results, 18F-FDG PET and PET/CT can be recommended as
early diagnostic modality in the workup for carcinoma of
unknown primary and neck metastases (Figure 2).
4. Treatment Response Assessment
In recent years, the use of combined chemoradiotherapy
(CRT) has been shown to have a signiﬁcant impact on the
treatment of head and neck cancer [56]. 18F-FDG PET is a
valuable modality for monitoring response to treatment as
it can assess metabolic activity rendering malignant process.
Martin et al. demonstrated in a recent study including
78 patients that PET was signiﬁcantly superior to clinical
examination or conventional imaging with respect to the
assessment of patients after chemoradiotherapy. Accuracy
of PET in therapy response assessment was signiﬁcantly
better than clinical assessment and conventional imaging
(CT/MR) (P<. 002 and P<. 001, resp.). The authors
also suggested that patients with a complete response on
posttreatment PET have a signiﬁcant survival advantage
[57].
Monitoring response to radiation therapy can be com-
plex due to posttreatment changes like inﬂammation and
edema. 18F-FDG PET has been investigated in the assess-
mentofearlyresponsetochemotherapyregimenandifmod-
iﬁcation or discontinuation are needed or not (Figure 3).
Several reports have illustrated that patients with favorable
response to therapy demonstrate a continued reduction
in metabolic activity and hence decreased FDG uptake
over multiple PET studies compared to baseline values.
Prognostic value of 18F-FDG PET regarding survival and
response to therapy appears promising but needs more
conﬁrmation.
5.Residual andRecurrentDisease
The utility of anatomical imaging in the posttreatment
situation is limited because of ﬁbrosis, tissue edema, and
anatomical distortion [58, 59]. The early detection of resid-
ual or recurrent head and neck cancer following radiation
therapyand/orchemotherapyposesadiagnosticchallenge.A
surveyoftheliteratureshowedthat18F-FDGPETisthemost
sensitive noninvasive modality presently available for diﬀer-
entiating posttreatment changes from residual or recurrentJournal of Oncology 5
Table 3: Studies evaluating performance of 18F-FDG PET or PET/CT for the detection of carcinoma of unknown primary in patients with
negative workup.
Author year Number of patients All positive True positive False positive Percent detected by
PET
Padovani et al. [46], 2009 13 9 7 2 54%
Silva et al. [47], 2007 25 9 3 6 12%
Fakhry et al. [48], 2006 20 10 7 3 35%
Wong and Saunders [49], 2003 17 8 5 3 29%
Fogarty et al. [50], 2003 21 6 1 5 5%
Johansen et al. [51], 2002 42 20 10 10 24%
Kresnik et al. [52], 2001 15 12 11 1 73%
Jungehulsing et al. [53], 2000 27 7 7 0 26%
Total 180 81 51 30 28%
Figure 2: A 61-year-old man presented with right side cervical lymphadenopathy proved to be carcinoma of unknown primary. Patient
underwent PET/CT to reveal primary tumor. Axial PET, CT, PET/CT, and maximum intensity projection (MIP) images are shown.
PET/CT showed asymmetrical FDG uptake in the palatine tonsils with intense FDG uptake in the right tonsil (black arrow) as well as
multiple hypermetabolic cervical lymph nodes in the right side (red arrows). This patient subsequently underwent surgical resection and
histopathology revealed squamous cell carcinoma in the right tonsil. PET/CT was valuable in revealing the primary tumor in this case.
disease and that its performance is higher compared CT and
MR for this purpose.
6. ResidualDisease
A 3-4 months interval between the end of radiotherapy
and evaluation of residual malignant tissue provides the
best speciﬁcity and sensitivity for PET. This is due to
reducing false positive ﬁndings associated with nonspeciﬁc
inﬂammatory activity, and reducing false negative ﬁndings
encountered during ﬁrst 8 weeks postchemoradiotherapy
which may increase the risk of seeding the dissection scar
if viable tumor cell was left in the tumor bed [60–67].
The NPV of PET following therapy is very high (up to
97%) and associated with a very good prognosis, whereas
positive 18F-FDG PET must be correlated with clinical
status and a biopsy is needed to rule out nonspeciﬁc uptake
[60, 61, 64–67]. Performance of 18F-FDG PET early after
chemoradiotherapy has been evaluated to assess residual
t u m o ra sm a n ys u r g e o n sp r e f e rt op e r f o r ms a l v a g es u r g e r y
within 6 to 8 weeks after radiation, before postradiation
ﬁbrotic changes develop. Kim et al. found in a prospective
study in 97 patients that early imaging one month following
completion of radiation therapy can be performed with high
sensitivity (88%) and speciﬁcity (95%) [68]. Delbeke and
Martin and Kostakoglu and Goldsmith agreed in two reviews
that persistent tumor uptake one month after radiation
therapy is strongly suggestive of residual disease and that6 Journal of Oncology
(a)
(a) (b) (b)
Figure 3: 40-year-old women with right side larynx squamous cell carcinoma and a right side cervical lymph node metastases underwent
PET/CT imaging before and 1 month after completion of chemoradiotherapy. (a) Pretherapy axial PET, CT, PET/CT, and MIP images reveal
intense FDG uptake in the right cervical lymph node (arrows). (b) After treatment axial PET, CT, PET/CT, and MIP images reveal decrease
FDG uptake in the corresponding locations (arrows). Appearance was consistent with early response to chemoradiotherapy. FDG PET/CT
was valuable in monitoring early response to treatment.
a positive PET scan can result in immediate initiation of
secondary treatment strategies due to early detection of
resistance to chemotherapy [69, 70]. On the other hand,
Rogers et al. found in a prospective study with a small
number of patients (12 patients) a low sensitivity of 45%
for a 1-month posttherapy 18F-FDG PET, compared to the
6–8 week posttreatment surgical histopathology [71]. The
current role of 18F-FDG PET and PET/CT are indicated
to exclude residual disease and to select patients who are
candidates for salvage surgery after chemoradiotherapy.
Although there is general consensus that waiting 3 months
postradiation sustains best sensitivity and speciﬁcity, early
imaging is justiﬁed in some scenarios, but with cautious
interpretation considering time interval posttherapy and
clinical ﬁndings.
The possible role of 18F-FDG PET in avoiding patients
futile neck dissection after treatment by excluding residual
locoregional disease has also been evaluated. Ong et al.
demonstrated in a recent study comprising 65 patients
that 18F-FDG PET/CT has a high negative predictive value
(NPV) and speciﬁcity (97% and 89%, resp.) for excluding
residual locoregional disease after chemoradiotherapy and
that neck dissection may be omitted safely in patients
without lymphadenopathy, while in patients with residual
lymphadenopathy, a lack of abnormal 18F-FDG uptake in
these nodes also excludes viable tumor with high certainty
but still further assessment is needed [72]. Yao et al. sug-
gestedthat18F-FDGPETcanavoidpatientneckdissectionif
the postradiotherapy 18F-FDG PET scan is negative since it
hashadahighpredictivevaluefornegativepathologyinneck
dissection or ﬁne-needle aspiration even with large residual
lymphadenopathy [73]. Nevertheless, Tan et al. found in
a retrospective study comprising 48 patients that 18F-FDG
PET was not a good predictor of residual disease [74].
Standardization of the role of 18F-FDG PET in avoiding
neck dissection in a prospective study particularly when
lymphadenopathy presents is necessary before negative 18F-
FDG PET/CT may become the only, or at least most-
decisive, criterion in the management of the neck after
chemoradiotherapy.
7. Recurrence
Klabbers et al. reviewed studies published between 1994 and
early 2003 regarding the utility of 18F-FDG PET for detec-
tion of residual and recurrent head and neck tumors after
radiation and/or chemoradiotherapy. The results showed
that 18F-FDG PET has a better sensitivity (86%) and
speciﬁcity (73%) compared with CT and/or MRI (56%
sensitivity and 59% speciﬁcity, resp.) [75]. Ryan et al.
reported on 108 patients and found that 18F-FDG PET/CT
detectedlocoregionallypersistingorrecurrentheadandneck
SCC with a sensitivity of 82%, a speciﬁcity of 92%, a positive
predictive value (PPV) of 64%, a negative predictive value
(NPV) of 97%, and an overall accuracy of 90% [76].
18F-FDG PET and PET/CT have a high sensitivity and
moderate speciﬁcity for detecting recurrent disease at the
primary tumor site, regional lymph node metastases, and
distantmetastases.Wongperformedameta-analysisonstud-
ies published between 1999 and 2002 that showed relatively
high sensitivity (84–100%) with moderate speciﬁcities (61–
93%)regarding18F-FDGPETinrecurrenttumorofHNCSC
[84].Severalstudiespublishedinthelast4yearsontheutility
of PET or 18F-FDG PET/CT for the detection of recurrenceJournal of Oncology 7
Table 4: Studies evaluating the performance of 18F-FDG PET and PET/CT for the detection of recurrent disease in head and neck cancers.
Authors year Number of patients Sensitivity Speciﬁcity Accuracy Notes
Abgral et al. [77], 2009 91 100% 85% 90% FDG PET/CT
Wang et al. [78],2009 44 100% 98% 98%
Prospecrive
PET performance > CT
Cermik et al. [79], 2007 50 83% 93%
´ Alvarez P´ erez et al. [80], 2007 60 98% 90% Prospective
Salaun et al. [81], 2007 30 100% 95% 97%
Goerres et al. [82], 2004 26 91% 93% Prospective




are summarized in Table 4. The performance of PET with
respect to the identiﬁcation of recurrent disease following
treatment demonstrated a high sensitivity (83%–100%) and
relatively high speciﬁcity (78%–95%). The higher speciﬁcity
in these studies compared to an earlier report, published by
Wong et al., may be related to more awareness of proper time
point (2-3 months) for imaging after treatment.
8. PET/CTinRadiationTreatment Planning
New high-precision radiotherapy (RT) techniques, such
as intensity-modulated radiation therapy (IMRT), 3-
dimensional conformal radiotherapy (3D-CRT), and proton
beam therapy allow conformal treatment of tumor and
to avoid unacceptable damage to normal tissues leading
to possible improvement of tumor control and decrease
of treatment-related toxicity. These techniques depend
on imaging modalities allowing accurate tumor volume
delineation and response assessment during treatment. The
potential application of 18F-FDG PET/CT for intensity
modulated radiation therapy (IMRT) planning is an area of
major interest. PET/CT may increase the gross target volume
(GTV) because metabolically active tumor can be detected
in normal-sized nodes. On the other hand, PET/CT-based
target volume could be smaller than CT-based target
volume alone in the case of patients in whom the tumor
may be partially necrotic. The radiation treatment plan
might be modiﬁed signiﬁcantly if distant metastases are
detected on the PET scan. The radiation target volumes
may be signiﬁcantly modiﬁed when 18F-FDG PET data are
incorporated into radiation treatment planning. However,
PET has been found to fail frequently to identify viable
tumor in areas of bone marrow inﬁltration and perineural
extension that are highly suspect on MRI (21).
Soto et al. suggested recently, based on a retrospective
study comprising 61 patients, that 18F-FDG PET/CT should
play an important but not exclusive role in deﬁning the gross
target volume (GTV) depending on the correlation between
pretreatment 18F-FDG PET-deﬁned biologic target volume
(PET-BTV) and the anatomical sites of locoregional failure
(LRF)after3-DCRTorIMRTforheadandneckcancer[85].
Rothschild et al. reported in a recent case control analysis
of 45 patients with pharyngeal carcinoma that PET/CT and
treatment with IMRT improved cure rates compared to
patients undergoing IMRT without PET/CT. The event-free
survival rate of the PET/CT-IMRT group was 90% and 80%
at 1 and 2 years, respectively, compared to 72% and 56% in
the control group without PET/CT (P = .005) [86].
Wang et al. investigated 28 patients with head and
neck carcinoma treated with IMRT based on an 18F-
FDG PET/CT deﬁned gross tumor volume (GTV). They
reported that tumor staging was signiﬁcantly changed in
50% of cases (14/28 patients) as compared with CT-based
staging, with 12 patients having higher T stages and 6
patients having higher N stages. Furthermore, a 17 months
median follow-up period posttherapy did not reveal any
locoregionalrecurrenceindicatingthatPET-guidedplanning
of the radiation ﬁeld is accurate [87].
On the other hand, Breen et al. reported that GTV
assessment in 10 patients with HNSCC was not signiﬁcantly
diﬀerent between PET/CT and contrast CT scans, using 8
diﬀerent observers. Furthermore, Breen et al. noted that
there was greater consistency for the CT derived GTV’s
compared to the PET/CT derived volumes [88]. Table 5
summarizes recent studies on the use of 18F-FDG PET in
radiotherapy planning. Ahn and Garg suggested in a review
that the utility of a functional assay in deﬁning target volume
helps to determine areas to receive higher doses of radiation
in cancers of the head and neck tumors [94].
One of the most controversial and challenging issues in
applying PET/CT in radiation planning is contouring the
outline of the tumor. Changing the PET window level can
lead to a considerable overestimation or underestimation
of the target volume. However, several techniques including
threshold-based methods and gradient-based methods have
been suggested and used, but still consensus needs to be
met. Fifty percent of the tumor/image maximum intensity
have been used for contouring by several groups [9, 95].
Others normalized volumes according to liver uptake [89,
91]. Wang et al. used an arbitrary SUV of 2.5 as a basis
for contouring [87]. Berson et al. suggested in a recent
report that developing an institutional contouring protocol8 Journal of Oncology
Table 5: Studies evaluating the role of FDG PET and PET/CT in radiation planning.
Author year Number of patients Study type Results Notes
Soto et al. [85],
2008
61 (9 LRF) Retrospective 8/9 LRF within BTV-PET.
Rothschild et al.
[86], 2007








diﬀerent from CT scans alone in
50% of cases
PET/CT upgraded T
and N stage in 18 p.
Breen et al. [88],
2007
10
no signiﬁcant diﬀerences in the







signiﬁcantly smaller than CT.
Koshy et al. [90],
2005
36 Retrospective TNM changed in 36%, RT
volume and dose changed in 14%
Heron et al. [91],
2004
21 Prospective PET/CT improves delineation of
normal tissues from tumor areas
PET/CT improves
staging
Ciernik et al. [92],
2003




21 PET improves GTV, normal
tissue sparing PET alone
(IMRT) intensity-modulated radiation therapy, (GTV) gross target volume, (BTV) biological target volume, (LRF) locoregional failure
for PET/CT treatment planning is highly recommended to
reduce interobserver variability [96]. Geets et al. compared
gradient-based method and threshold-based method in
patients with laryngeal cancer. They demonstrated that the
gradient-based method is more accurate than the threshold-
based method. The threshold-based method overestimated
the true volume by 68% (P = .014) [97].
Although most authors demonstrated that PET/CT can
change the gross tumor volume (GTV) and staging status for
radiotherapy planning. Several issues are still to be addressed
before the role of PET/CT for IMRT planning and gross
tumor volume (GTV) delineation can be clearly deﬁned.
Is this change in GTV clinically signiﬁcant? Can PET/CT
provide prognostic information guiding the escalating of the
radiation dose to area with higher metabolic activity? Fur-
thermore, is the development of objective and reproducible
methods for segmenting PET images achievable? Addressing
these issues will help to identify the ultimate impact of this




PET imaging has become a promising tool for detect-
ing hypoxic subvolumes of tumors. Hypoxia represents
a negative prognostic factor for radiation treatment of
head and neck cancer where it is associated with a sig-
niﬁcant resistance to radiochemotherapy [98, 99]. How-
ever, mapping hypoxic region of tumor can positively
impact on treatment outcome [100]. Several PET tracers
have emerged for this purpose like 18F-ﬂuoromisonidazole
(18F-FMISO), 18F-labelled ﬂuoroazomycin arabinoside
(-[18F]FAZA and 2-(2-nitro-(1)H-imidazol-1-yl)-N-(2,2,3,
3,3-pentaﬂuoropropyl)-acetamide (EF5) [100–102]. Chao et
al. demonstrated the feasibility of Cu(II)-diacetyl-bis(N(4)-
methylthiosemicarbazone) (60Cu-ATSM PET) to create a
hypoxia imaging-guided IMRT treatment plan through
coregisteringhypoxia60Cu-ATSMPETtothecorresponding
CT images for radiation therapy of patients with head and
neck cancer [103]. At our institution, Souvatzoglou et al.
18F-labelled ﬂuoroazomycin arabinoside (18F-FAZA) as a
feasible hypoxic agent in patients with head and neck cancer
and demonstrated that FAZA can be potentially used for
hypoxia-directed intensity-modulated IMRT dosing patients
[104].
While 18-18F-FDG PET is very sensitive head and
neck cancers, its speciﬁcity is not as high as its sensitivity
due to false-positive results in inﬂammatory or infectious
lesions. These lesions are frequent in this area, in particular
after treatment by surgery and/or radiotherapy. For this
purpose, O-(2-[18F]ﬂuoroethyl)-L-tyrosine (18F-FET) has
been introduced and investigated by several groups. Results
suggested a possible role for FET in head and neck cancer
to diﬀerentiate between inﬂammatory and malignancy in
a selective cases. Nevertheless, it should not be used as
alternative to FDG due to inferior sensitivity [105, 106].
The proliferation marker ﬂuorodeoxythymidine 18F-3-
deoxy-3-ﬂuorothymidine(18F-FLT)hasbeeninvestigatedby
de Langen et al. in 15 patients (including 6 patients with
HNC) to evaluate the reproducibility of quantitative 18F-
FLT measurements. The authors showed that quantitativeJournal of Oncology 9
(a) (b) (c)
(d)
Figure 4: Patient with a squamous cell carcinoma of the right mandible (arrows). (a) The [18F]Galacto-RGD PET shows heterogeneous
tracer uptake, which can also be clearly delineated in (b) the image fusion with the corresponding MRI scan. (c) shows the tumour volume
in red as deﬁned by MRI. By applying a threshold of SUV 3 and only using pixels with SUVs above this threshold, (d) a subvolume with
more intense αvß3 expression can be deﬁned which is shown in the 3D reconstruction (blue line in (c), blue area in (d)).
18F-FLT measurements are reproducible for predicting
response to therapy in individual patients. However, authors
recommended further studies correlating 18F-FLT response
with pathological and clinical outcome [107].
Beer et al. investigated the application of [18F] Galacto-
RGD-PET imaging of αvß3 expression, a receptor related
to tumor angiogenesis and metastasis, in 11 patients with
head and neck squamous cell carcinoma (HNSCC). Their
results showed that use of 18F-RGD PET in a multi-
modalities setting and deﬁnition of tumor subvolumes is
feasible(Figure 4).Theauthorssuggestedthat18F-RGDPET
imaging might be used for the assessment of angiogenesis
and for planning and response evaluation of αvß3 targeted
therapies [108].
In the preclinical settings, the role of molecular imaging
with PET for monitoring the antiepidermal growth factor
receptor (anti-EGFR) inhibitor therapy in solid tumors
showing overexpression of EGFR like head and neck squ-
mouscellcarcinoma(HNSCC)hasbeeninvestigated.Several
radiopharmaceuticalsincluding theproliferationmarkerﬂu-
orodeoxythymidine (18F-FLT) and the chimeric monoclonal
antibody (64CU-DOTA-Cetuximab) have been considered
promising for this purpose. However, further clinical and
imaging studies are still needed.
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